Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Peak Bio, Inc. (PKBO)

1.43   -0.22 (-13.33%) 01-27 15:52
Open: 1.53 Pre. Close: 1.65
High: 1.5741 Low: 1.43
Volume: 3,526 Market Cap: 29(M)

Technical analysis

as of: 2023-01-27 4:47:07 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 4.7     One year: 6.89
Support: Support1: 1    Support2: 0.84
Resistance: Resistance1: 4.03    Resistance2: 5.9
Pivot: 1.81
Moving Average: MA(5): 1.6     MA(20): 2.36
MA(100): 6.71     MA(250): 8.6
MACD: MACD(12,26): -0.9     Signal(9): -1
Stochastic oscillator: %K(14,3): 14     %D(3): 15.3
RSI: RSI(14): 26.1
52-week: High: 15  Low: 1
Average Vol(K): 3-Month: 404 (K)  10-Days: 8 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PKBO ] has closed above bottom band by 32.0%. Bollinger Bands are 27.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.58 - 1.59 1.59 - 1.59
Low: 1.4 - 1.42 1.42 - 1.43
Close: 1.41 - 1.43 1.43 - 1.44

Company Description

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

Headline News

Mon, 09 Jan 2023
Healthcare Stocks Moving Monday: CINC, APGN, AMYT, ALBO, PKBO, CERS, CUTR, ARWR - InvestorsObserver

Mon, 09 Jan 2023
U.S. shares mixed at close of trade; Dow Jones Industrial Average ... - UK

Mon, 09 Jan 2023
U.S. stocks mixed at close of trade; Dow Jones Industrial Average ... -

Mon, 28 Nov 2022
Healthcare Stocks Moving Monday: AXSM, NUTX, KTRA, IOBT, CINC, TCBP, PKBO, ONCS - InvestorsObserver

Fri, 04 Nov 2022
What Is Going on With Peak Bio (PKBO) Stock Today? - InvestorPlace

Thu, 03 Nov 2022
Peak Bio Stock (OTC:PKBO), Quotes and News Summary - Benzinga

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 20 (M)
% Held by Insiders 3.2e+006 (%)
% Held by Institutions 39.3 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -8.85e+006
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 839.2
Return on Equity (ttm) 0
Qtrly Rev. Growth 489990
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow -6 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.